UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the Quarterly Period ended December 31, 1999
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ___________to _________
Commission file number 000-14242
CELSION CORPORATION
--------------------
(Exact name of registrant as specified in its charter)
Maryland 52-1256615
-------- ----------
State or other jurisdiction of (I.R.S. Employer
incorporation or organization Identification No.)
10220-I Old Columbia Road, Columbia, Maryland 21046-1705
--------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (410) 290-5390
--------------
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
As of December 31, 1999, the Registrant had outstanding 54,188,294 shares of
Common Stock, $.01 par value.
-1-
Item 3. Defaults upon Senior Securities
None.
Item 4. Submission of Matters to a Vote of Securities Holders
None.
Item 5. Other Information
On February 7, 2000, the Company issued a call for redemption of its
Series 700 and Series 800 Warrants, which enable the holders thereof to purchase
shares of Common Stock at prices of $1.00 and $0.90 per share, respectively. The
Series 700 Warrants relate to a total of 2,583,000, and the Series 800 Warrants
relate to a total of 2,610,000 shares of Common Stock. The Company anticipates
that a substantial number of Series 700 and Series 800 Warrants will be
exercised since the redemption price for such Warrants is equal to only $0.01
per share. Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
3. Articles Supplementary amending the Articles of
Incorporation of the Company filed January 31, 2000
with the State of Maryland*
10.1 Employment Agreement between the Company and Spencer
J. Volk dated January 14, 2000*
10.2 Employment Agreement between the Company and
Augustine Y. Cheung dated January 14, 2000*
11. Computation of per share earnings
27. Financial Data Schedule
*Exhibits filed with this Amendment.
(b) Reports on Form 8-K.
Form 8-K was filed on February 3, 2000, reporting on the
completion of a recent private placement financing and a
related capitalization change, new executive employment
agreements and commencement of clinical trials. No financial
statements were filed with the Form 8-K.
-2-